WO2007084721A2

WO2007084721A2 - Skin protection and moisturizing compositions and methods

Info

Publication number: WO2007084721A2
Application number: PCT/US2007/001536
Authority: WO
Inventors: Thomas E. Mower
Original assignee: Sakura Properties LLC
Current assignee: Sakura Properties LLC
Priority date: 2006-01-18
Filing date: 2007-01-18
Publication date: 2007-07-26
Anticipated expiration: 2008-07-18
Also published as: WO2007084721A3

Abstract

Compositions and methods relating to partially hydrolyzed fucoidan for use in skin care compositions are described. Fucoidan from brown seaweeds is partially hydrolyzed and then mixed with other ingredients for use as a' skin care composition in cream, lotion, ointment, or other form. The fucoidan is partially hydrolyzed with acid and heat. The partially hydrolyzed fucoidan may also be sulfonated. Other ingredients that may be included in the skin care composition include anti-wrinkle compounds, radiation protecting agents, fragrances, proteins, colorants or coloring agents, lipids, vitamins, botanical extracts, glycolipids, polymers, and copolymers, and the like. An article with skin-protecting and moisturizing compound includes a tissue substrate, a base, and partially hydrolyzed fucoidan.

Description

SKIN PROTECTION AND MOISTURIZING COMPOSITIONS AND METHODS

BACKGROUND OF THE INVENTION

The present Invention relates generally to fucoidan compositions and methods for skin protection and moisturizing and, more particularly, to compositions for treating and repairing the skin, especially in application to damaged skin, treating wrinkles, and protecting skin from ultraviolet damage.

The skin is made up of two major layers. The epidermis is the top layer and forms a protective covering for skin and controls the flow of water and substances in and out of the skin. To stay healthy, the skin has to cope with changing environmental conditions and repair damage at the same time. The skin is in a constant state of repair as it sheds the dead cells on the surface and replenishes the lower layers. The dermis is the lower level of the skin and is the layer that provides the strength, elasticity, and thickness to the skin. Cells in the dermis are responsible for synthesis and secretion of all the dermal matrix components, such as collagen, elastin, and glycosaminoglycans. Collagen provides the strength, elastin the elasticity, and glycosaminoglycans the moistness and plumpness of the skin. The stratum corneum is the outer-most layer of the skin and is responsible for regulating skin water levels and functioning as a barrier against chemicals and other stressors found in the environment. The complex arrangement of lipids in the intercellular space of the stratum corneum is responsible for the establishment of normal barrier function. Multi-layered structures of cholesterol, ceramides, and fatty acids, as well as some other minor lipids, provide the major barrier to the transport of hydrophilic substances into or through the skin. The link between the barrier function and skin health is apparent from the skm inflammation caused by lipid extraction from the skin.

Skin barrier can be damaged due to a number of mechanisms. One mechanism for damage is physical abrasion, which may be caused by repeated rubbing of tissue products, such as facial or bath tissue, on the skin. With physical abrasion, layers of the skin are stripped away causing damage to the stratum corneum. Also, biological fluids, such as urine, feces, nasal and vaginal secretions, may contain a variety of components that can damage the stratum corneum. Some specific examples include proteases, lipases, bile acids, and fatty acids. Once the stratum corneum barrier is compromised, skin inflammation can occur.

The skin may be abused by soaps, emulsifier-based cosmetics, hot water, or organic solvents, for example. These each contribute to rob the skin of essential moisture, and to create a stressed barrier that does not function properly. Moisture loss and irritation increases, leaving the skin sensitive, scaly, and dry. Free-radical activity multiplies, causing more wrinkles and premature aging.

Furthermore, the skin is subject to deterioration through dermatological disorders, environmental abuse, such as from wind, air conditioning, and central heating, or through the normal aging process, which may be accelerated by exposure of skin to sun. The thickness of the dermal layer is reduced due to aging, thus causing the skin to slacken. This is believed to be partially responsible for the formation of wrinkles. In recent years, the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously.

Still further, skin damage from sunlight has been noted for many years. Recently, there has been a link established between skin cancer and exposure to harmful solar radiation. Damage may be caused by ultraviolet (UV) radiation. UV radiation may be broken into two major categories: UV-A (320-400nm wavelength) which penetrates deeper into the skin (to the dermis and beyond), and UV-B (290-320nm wavelength) which possesses an intense physiopatho logical activity on the skin; these are absorbed just above the dermis and they are responsible for erythema and skin pigmentation. The energy from UV-A is much lower and the photobiological effects they cause are much more long term in nature, for example, they accelerate skin aging.

Excessive hydration of the skin can also have a negative impact on skin barrier. The hydration level of diapered skin, for example, may reach between five and ten times that of undiapered skin. Frequent contact of diapered skin with fluids such as urine and feces may also contribute to increased hydration. Increased skin hydration disrupts skin lipid organization in the stratum corneum, and may increase the skin permeability of irritants, thus increasing the risk of skin inflammation.

Tissue products, such as bath and facial tissue, are commonly used to absorb body fluids and leave the skin dry. These products, in addition to absorbing and wiping fluids, however, also abrade the skin during use and frequently do not leave the skin completely dry and free of the body fluid after use. During frequent use of these products, the skin can become so dry and/or abraded as to appear red and be sore to the touch. To reduce this problem, additive formulations have been applied to tissue products to provide lubricity and moisture. Once deposited on the skin, these products may provide a skin benefit by occluding the skin and protecting the stratum corneum until the damage is repaired.

To date, the moisturizing and/or lubricating formulations applied to tissue products have not been completely satisfactory. Many formulations to date have proven to be unstable, even at slightly elevated temperatures and have tended to migrate into the product matrix prior to use where the formulation is only of minimal, if any benefit. Additionally, many formulations used to date have had very poor transfer rates from the product to the skin where it can be of use. As such, it is apparent that there is a commercial need for hydrophilic lubricating formulations suitable for use in combination with tissue products, such as facial tissue and bath tissue. It would be advantageous if the lubricating formulation could provide a moisturization benefit to alleviate skin dryness, as well as present a soft, esthetically pleasing feel to reduce friction between the product and skin. Also, it would be advantageous if the lubricating formulations were formulated to be fluid during processing and rapidly solidify after application to the products.

Consumers are increasingly seeking anti-aging cosmetic products that treat or delay the visible signs of actual aging and weathered skin, such,as wrinkles, lines, sagging, hyper-pigmentation, and age spots. Consumers also frequently seek other benefits from cosmetic products in addition to anti-aging. The concept of sensitive skin has raised the demand for cosmetic products that improve the appearance and condition of sensitive, dry, and flaky skin and soothe red or irritated skin. Consumers also desire cosmetic products that treat spots, pimples, blemishes, and so forth.

Research shows that using a skin care product that includes the skin's natural building blocks speeds the skin's ability to repair itself and keeps the barrier function of skin at optimal levels. This approach treats the problem, not merely the symptom. Irritation stops before it may start, so recurring problems are avoided, thus bringing the skin back to ideal conditions.

Consumer demand for natural-based products has been growing in recent years. Chemical synthesis is perceived as environmentally unsafe. A chemically synthesized ingredient may contain harsh chemicals. Natural products are perceived as pure and mild and thus superior to chemically synthesized products. Delivering a cosmetic benefit from plant sources, however, is not trivial. To derive a real benefit from a natural source, not only does a plant or a part of the plant containing a specific active ingredient have to be identified, but a minimum concentration and/or a specific extract of that plant has to be identified that truly delivers a cosmetic benefit. Accordingly, consumers demand an effective treatment for the skin and wrinkles that moisturizes, heals, and soothes the vulnerable and delicate surface of the skin. Further, consumers demand that treatment for the skin be based on natural products to promote healing and preserve youthful appearance.

Fucoidan is a sulfated polysaccharide found in many sea plants and animals and is particularly concentrated in the cell walls of brown algae (Phaeophyceae). Fucoidan is a complex carbohydrate polymer composed mostly of sulfated L-fucose residues. These polysaccharides are easily extracted from the cell wall of brown algae with hot water or dilute acid and can account for more than 40% of the dry weight of isolated cell walls. O. Berteau & B. Mulloy, Sulfated Fucans, Fresh Perspectives: Structures, Functions, and Biological Properties of Sulfated Fucans and an Overview of Enzymes Active Toward This Class of Polysaccharide, 13 Glycobiology 29R-40R (2003). Fucoidan structure appears to be linked to algal species, but there is insufficient evidence to establish any systematic correspondence between structure and algal order. High amounts of α(l-3) and α(l-4) glycosidic bonds occur in fucoidans from Ascophyllum nodosum. A disaccharide repeating unit of alternating α(l-3) and α(l-4) bonds represents the most abundant structural feature of fucoidans from both A. nodosum and Fuciis vesiculosus, which are species of seaweed. Sulfate residues are found mainly in position 4. Further heterogeneity is added by the presence of acetyl groups coupled to oxygen atoms and branches, which are present in all the plant fucoidans. Following is a representation of A. nodosum fucoidan:

Fucoidan-containing seaweeds have been eaten and used medicinally for at least 3000 years in Tonga and at least 2000 years in China. An enormous amount of research has been reported in the modern scientific literature, where more than 500 studies are referenced in a PubMed search for fucoidan. The physiological properties of fucoidans in the algae appear to be a role in cell wall organization and possibly in cross-linking of alginate and cellulose and morphogenesis of algal embryos. Fucoidans also have a wide spectrum of activity in biological systems. They have anticoagulant and antithrombotic activity, act on the inflammation and immune systems, have antiproliferative and antiadhesive effects on cells, and have been found to protect cells from viral infection. Further, fucoidan has numerous beneficial functions that heal and strengthen different systems of the body, including anti-viral, anti-inflammatory, anti-coagulant, and anti-tumor properties. A.I. Usov et al., Polysaccharides of Algae: Polysaccharide Composition of Several Brown Algae from Kamchatka, 27 Russian J. Bio. Chem. 395-399 (2001). Fucoidan has been found to build and stimulate the immune system. Research has also indicated that fucoidan reduces allergies, inhibits blood clotting, fights diabetes by controlling blood sugar, prevents ulcers, relieves stomach disorders, reduces inflammation, protects the kidneys by increasing renal blood flow, and detoxifies the body. Fucoidan also helps to reduce and prevent cardiovascular disease by lowering high cholesterol levels and activating enzymes involved in the beta- oxidation of fatty acids.

A Japanese study found that fucoidans enhanced phagocytosis, the process in which white blood cells engulf, kill, digest, and eliminate debris, viruses, and bacteria. An American study reported that fucoidans increased the number of circulating mature white blood cells. An Argentine study and a Japanese study found that fucoidans inhibited viruses^", such as herpes simplex type I, from attaching to, penetrating, and replicating in host cells. A Swedish study is among the many that showed fucoidans inhibit inflammation cascades and tissue damage that may lead to allergies. Other studies, such as one in Canada, found that fucoidans block the complement activation process that is believed to play an adverse role in chronic degenerative diseases, such as atherosclerosis, heart attack, and Alzheimer's disease. Two American studies found that fucoidans increase and mobilize stem cells.

' Researchers have also determined that fucoidan tends to combat cancer by reducing angiogenesis (blood vessel growth), inhibiting metastasis (spreading of cancer cells to other parts of the body), and promoting death of cancer cells. Certain societies that make brown seaweed part of their diet appear to have remarkably low instances of cancer. For example, the prefecture of Okinawa, where the inhabitants enjoy some of the highest life expectancies in Japan, also happens to have one of the highest per capita consumption rates of fucoidans. It is noteworthy that the cancer death rate in Okinawa is the lowest of all the prefectures in Japan.

Brown seaweed, a ready source of fucoidan, is found in abundance in various ocean areas of the world. One of the purest locations that provides some of the highest yields of fucoidan is in the clear waters surrounding the Tongan islands, where the seaweed is called Iimu moui. In Japan, hoku kombu {Laminaria japonica), is said to be particularly rich in fucoidans and is similar to Iimu moui. The Japanese also consume at least two other types of brown seaweed-wakame and mozuku (Cladosiphon and Nemacystus).

Typically, about four percent by weight of Tongan Iimu moui is fucoidan. There are at least three types of fucoidan polymer molecules found in brown seaweed. U-fucoidan, having about 20 percent glucuronic acid, is particularly active in carrying out cancer cell destruction. F-fucoidan, a polymer of mostly sulfated fucose, and G-fucoidaπ, which contains galactose, both tend to induce the production of HGF cells that assist in restoring and repairing damaged cells. All three types of fucoidan also tend to induce the production of agents that strengthen the immune system. What is needed is a skin care composition that solves one or more of the problems described herein and/or one or more problems that may come to the attention of one skilled in the art upon becoming familiar with this specification. One example of a problem not solved by the prior art are skin care compositions with natural ingredients that assist in slowing aging, regenerating damaged cells and tissues, promoting growth factors, include antioxidants, and/or fight free radicals. BRIEF SUMMARY OF THE INVENTION

The present invention has been developed in response to the present state of the art, and in particular, in response to the problems and needs in the art that have not yet been fully solved by currently available skin care compositions and methods. According to one illustrative embodiment, the present invention has been developed to provide a skin care composition including a mixture of partially hydrolyzed fucoidan and a base. The skin care composition may include from about 1 to about 95 parts by weight of the partially hydrolyzed fucoidan. The partially hydrolyzed fucoidan may be a derivative of Tongan limu moui seaweed, Japanese mozuku or kombu seaweeds, or mixtures of these seaweeds. The partially hydrolyzed fucoidan may be sulfonated. The base may be an oleaginous base. The oleaginous base may be a hydrocarbon base. The oleaginous base may be a silicone polymer. The oleaginous base may be a vegetable oil. The oleaginous base may be an animal fat. The base may be an absorption base. The base may be an emulsion base. The emulsion base may be an aqueous phase, an emulsifying agent, and an oleaginous phase. The base may be a water-soluble base. The water-soluble base may be a member selected from the group consisting of polyethylene glycols, bentonite, colloidal magnesium aluminum silicate, sodium alginate, glyceryl monostearate, cellulose derivatives, and mixtures thereof. The water-soliible base may be a cellulose derivative selected from the group consisting of methylcellulose, hydroxyethyl cellulose, and sodium carboxymethyl cellulose, and mixtures thereof.

In another illustrative embodiment, the present invention is drawn toward a skin moisturizing composition that includes a mixture of a partially hydrolyzed, sulfonated fucoidan, wherein the fucoidan is a derivative of the Tongan limu moui seaweed, and a base.

According to another illustrative embodiment of the invention, a skin care composition for the care of wrinkles is provided, the composition comprising partially hydrolyzed fucoidan, a base, and an anti- wrinkle compound.

According to another illustrative embodiment, the skin care composition may further include a derivative of the mangosteen plant. The skin care composition may further include honey. The skin care composition may further include a radiation protection agent.

According to yet another illustrative embodiment, the anti-wrinkle compound may be a flavonoid. The flavonoid may be one of the group consisting of: unsubstituted flavanone, mono-hydroxy flavanones, mono-alkoxy flavanones, unsubstituted chalcone, mono-hydroxy chalcones, di-hydroxy chalcones, and tri- hydroxy chalcones, unsubstituted flavone, 7,2'-dihydroxy flavoπe, 3',4'-dihydroxy naphthoflavone, 4'- hydroxy flavone, 5,6-benzoflavone, and 7,8-benzoflavone, unsubstituted isoflavone, daidzein, 5,7- dihydroxy-4-methoxy isoflavone, soy isoflavones, unsubstituted coumarin, 4-hydroxy coumarin., 7-hydroxy coumarin, 6-hydroxy- 4-methyl coumarin, unsubstituted chromone, 3-formy] chromone, 3-formyl-6- isopropyl chromone, unsubstituted dicoumarol, unsubstituted chromanone, unsubstituted chromanol, and mixtures thereof.

According to yet another embodiment is a method of making a skin care composition for the care of wrinkles, comprising the steps of producing partially hydrolyzed fucoidan by harvesting Tongan limu moui seaweed, removing extraneous material, mixing the Tongan limu moui seaweed with an aqueous buffer while heating, and filtering and mixing the partially hydrolyzed fucoidan with a base and an anti-wrinkle compound. In still another illustrative embodiment of the present invention, a composition for skin protection from ultraviolet damage for application to skin or hair includes a mixture of partially hydrolyzed fucoidan, a base, and a radiation protecting agent.

In one illustrative embodiment, the composition may include from about 0.05 to about 95 weight percent partially hydrolyzed fucoidan. The partially hydrolyzed fucoidan may be a derivative of one seaweed of the group consisting of: Tongan limu moui seaweed, Japanese mozuko seaweed, Japanese kombu seaweed, and combinations thereof. The partially hydrolyzed fucoidan may be sulfonated. The radiation protecting agent may be titanium dioxide. The radiation protecting agent may also be one selected from the group consisting of: p-aminobenzoic acid (PABA), avobenzone, cinoxate, dioxybenzone, homosalate, menthyl anthranilate, octocrylene, octyl methoxycinnamate (Octinoxate), ocry] salicylate, oxybenzone, padimate O, phenylbenzimidazole sulfonic acid, sulisobenzone, trolamine salicylate, aminobenzoic acid, 2 - ethyi hexyl-p- methoxycinnamate (commercially available as PARSOL MCX), 4,4'-/-butyl methoxydibenzoyl-methane (commercially available as PARSOL 1789), 2-hydroxy-4- methoxybenzophenone, octyldimethyl-p-aminobenzoϊc acid, digalloyltrioleate, 2,2-dihydroxy-4- methoxybenzophenone, ethyl -4-(bis(hydroxypropyl))aminobenzoate, 2-ethyl hexyl-2-cyano-3,3 diphenylacrylate, 2-ethyIhexylsalicylate, glyceryl-p-aminobenzoate, 3,3,5-tri-methylcyclohexylsalicylate, methyIanthranilate,/?-dimethyl-aminobenzoic acid or aminobenzoate, 2-ethylhexyl-/>-dimethyl- aminobenzoate, 2-phenylbenzimidazole-5-sulfonic acid, 2-(p-dimethylaminophenyl)-5-sulfonicbenzoxazoic acid, ensulizole, meradimate, octocrylene titanium dioxide, zinc oxide, and mixtures thereof. The base may be an oleaginous base. The oleaginous base may be a hydrocarbon base. The base may be an absorption base. The oleaginous base may be an aqueous base, an emulsifying agent, and/or an oleaginous phase. The base may include a water-soluble base.

According to another embodiment of the present invention, there is a composition for skin protection from ultraviolet damage for application to skin or hair, including a mixture of sulfonated and partially hydrolyzed fucoidan derived from Tongan limu moui seaweed, a base, and a radiation protecting agent.

According to another illustrative embodiment of the present invention, there is provided an article with skin-protecting and moisturizing compound, which includes a substrate, a base, and partially hydrolyzed fucoidan. According to still another embodiment of the present invention, there is provided a method of making an article with skin-protecting and moisturizing compound, which method includes providing a first tissue paper web, applying a base to the first tissue paper web, and applying partially hydrolyzed fucoidan to the first tissue paper web. The method may further include the step of applying a second tissue paper web to the first tissue paper web. The method may further include applying an anti-viral agent to the first tissue paper web. The method may further include applying an anti-viral agent to the second tissue paper web. The base and the partially hydrolyzed fucoidan may be combined before application to the tissue paper web. The partially hydrolyzed fucoidan may be sulfonated. The partially hydrolyzed fucoidan may be a derivative of one of the group consisting of: Tongan limu moui seaweed, Japanese wakame seaweed, Japanese mozuku seaweed, and combinations thereof. Reference throughout this specification to features, advantages, or similar language does not imply that all of the features and advantages that may be realized with the present invention should be or are in any single embodiment of the invention. Rather, language referring to the features and advantages is understood to mean that a specific feature, advantage, or characteristic described in connection with an embodiment is included in at least one embodiment of the present invention. Thus, discussion of the features and advantages, and similar language, throughout this specification may, but do not necessarily, refer to the same embodiment.

Furthermore, the described features, advantages, and characteristics of the invention may be combined in any suitable manner in one or more embodiments. One skilled in the relevant art will recognize that the invention may be practiced without one or more of the specific features or advantages of a particular embodiment. In other instances, additional features and advantages may be recognized in certain embodiments that may not be present in all embodiments of the invention.

These features and advantages of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.

DETAILED DESCRIPTION

Before the present fucoidan-containing skin care compositions and methods are disclosed and described, it is to be understood that this invention is not limited to the particular configurations, process steps, and materials disclosed herein as such configurations, process steps, and materials may vary somewhat. It is also to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof.

The publications and other reference materials referred to herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference. The references discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission mat the inventors are not entitled to antedate such disclosure by virtue of prior invention.

For the purposes of promoting an understanding of the principles of the invention, reference will now be made to the exemplary embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended. Any alterations and further modifications of the inventive features illustrated herein, and any additional applications of the principles of the invention as illustrated herein, which would occur to one skilled in the relevant art and having possession of this disclosure, are to be considered within the scope of the invention.

Reference throughout this specification to "one embodiment," "an embodiment," or similar language means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases "one embodiment," "an embodiment," and similar language throughout this specification may, but do not necessarily, all refer to the same embodiment, different embodiments, or component parts of the same or different illustrated invention. Additionally, reference to the wording "an embodiment," or the like, for two or more features, elements, etc. does not mean that the features are related, dissimilar, the same, etc. The use of the term "an embodiment," or similar wording, is merely a convenient phrase to indicate optional features, which may or may not be part of the invention as claimed.

Jt must be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a skin care composition containing "a partially hydrolyzed fucoidan" includes a mixture of two or more of such partially hydrolyzed fitcoidans, reference to "an acid" includes reference to two or more of such acids, and reference to "a preservative" includes reference to a mixture of two or more of^" such preservatives.

In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.

As used herein, "comprising," "including," "containing," "is," "are," "characterized by," and grammatical equivalents thereof are inclusive or open-ended terms that do not exclude additional, unrecited elements or method steps. "Comprising" is to be interpreted as including the more restrictive terms "consisting of and "consisting essentially of." As used herein, "partially hydrolyzed fucoidan" means fucoidan that has been hydrolyzed into smaller polymers and oligomers, but not so thoroughly hydrolyzed as to result in complete hydrolysis to substantially primarily monosaccharides.

As used herein, "lotions" are liquid cosmetics, often suspensions or dispersions, intended for external application to the body. As used herein, "creams" are soft cosmetic-type preparations. Creams of the oil-in-water (O/W) type include preparations such as foundation creams, hand creams, shaving creams, and the like. Creams of the water-in-oil (W/O) type include cold creams, emollient creams, and the like. Pharmaceutically, creams are solid emulsions containing suspensions or solutions of active ingredients for external application. Generally, preparations of this type are classified as ointments. Specifically, they belong to the emulsion- type bases.

As used herein, "ointments" are semisolid preparations for external application of such consistency that may be readily applied to the skin. They should be of such composition that they soften, but not necessarily melt, when applied to the body. They serve as vehicles for the topical application of active ingredients and also function as protectives and emollients for the skin. For many years ointments were limited by definition and use to mixtures of fatty substances. Today, in addition to such oleaginous mixtures, there are ointment preparations possessing the same general consistency but entirely free of oleaginous substances. In many instances, they are emulsions of fatty or wax-like materials with comparatively high proportions of water. These emulsions may be either water-in-oil (W/O) or oil-in-water (O/W) emulsions, depending primarily on the selection of the emulsifying agent. Such semisolid emulsions are also referred to as creams. Creams and ointments containing large amounts of insoluble powders are referred to as pastes. Pastes are usually stiffer and more absorptive than creams and ointments.

Each statement of an embodiment is to be considered independent of any other statement of an embodiment despite any use of similar or identical language characterizing each embodiment. Therefore, where one embodiment is identified as "another embodiment," the identified embodiment is independent of any other embodiments characterized by the language "another embodiment." The independent embodiments are considered to be able to be combined in whole or in part one with another as the claims and/or art may direct, either directly or indirectly, implicitly or explicitly.

Finally, the fact that the wording "an embodiment," or the like, does not appear at the beginning of every sentence in the specification, such as is the practice of some practitioners, is merely a convenience for the reader's clarity. However, it is the intention of this application to incorporate by reference the phrasing "an embodiment," and the like, at the beginning of every sentence herein where logically possible and appropriate.

An illustrative embodiment of the present invention advances prior art skin care compositions by providing a skin care composition formulated with fucoidan from seaweed, such as limu moui, kombu, or mozuku. The addition of fucoidan to the skin care composition of the present invention serves to provide significant advantages not found in prior art skin care compositions. The fucoidan-enhanced skin care compositions of the present invention provides many beneficial functions, including providing for anti-aging, and regeneration of cells and tissues; promoting youthfulness; reducing inflammation and the like. In addition, the fucoidan-enhanced skin care compositions of the present invention minimize the visible signs of both biological and environmental aging. That is, the present skin care compositions slow the aging process, assist in regenerating damaged cells and tissues, and promote growth factors in the body. Fucoidan is high in antioxidants that help to fight free radical damage to the body that may lead to cancer. These antioxidants help to fight free radical damage caused by the sun and other changing environmental conditions and elements. Another illustrative embodiment of the present invention includes a skin care composition that includes partially hydrolyzed fucoidan, a base, and another anti-wrinkle compound. The skin care composition of the present invention may be formulated to be applied to skin, and more specifically to be applied to skin to prevent and/or diminish wrinkles in the skin.

Brown seaweed, a source of fucoidan, grows in many oceans, including off the coasts of Japan and Okinawa, Russian coastal waters, Tonga, and other places. An excellent source of fucoidan is the limu moui sea plant growing in the waters of the Tongan islands. This brown seaweed contains many vitamins, minerals, and other beneficial substances and is particularly rich in fucoidan.

Typically, the brown seaweed grows in long angel hair stems with numerous leaves. The fucoidan ingredient is found in natural compositions on the cell walls of the seaweed, providing a slippery sticky texture that protects the cell walls from the sunlight.

In one embodiment, a kombu-type or mozuku-type seaweed is harvested from the coastal waters of the Tongan islands. These seaweeds can be manually harvested , including stems and leaves, by divers and cleaned to remove extraneous materials. The seaweed is then usually frozen in large containers and shipped to a processing plant. In processing, the heavy outer fibers must first be broken down to provide access to the fucoidan component. If frozen, the seaweed material is first thawed, but if not frozen, then the seaweed material is placed in a mixing vat and shredded, while being hydrolyzed with acids and water. The material may optionally be sulfonated with sulfuric acid to help in breaking down the heavy cell fibers. The mixture is also buffered with citric acid and thoroughly blended to maintain suspension. The material may also be heated at atmospheric or greater than atmospheric pressure while mixing. The resulting puree is tested and maintained at a pH of about 2 to 4 so as to remain acidic, enhancing preservative and stability characteristics. The puree may be used in preparing skin care products. Alternately, the mixture may be refrozen in small containers for later processing. According to one embodiment, the present invention provides a skin care composition formulated with fucoidan compositions from seaweed, such as the limu moui seaweed plant, the Japanese mozuku seaweed, or Japanese kombu seaweed, or mixtures thereof. In another embodiment, the fucoidan may be partially hydrolyzed fucoidan. In yet another embodiment, the fucoidan may be sulfonated. According to a further embodiment, the fucoidan compositions are present in selected embodiments in the amount of at least about 0.05 weight percent, or at least about 3 weight percent, or at least about 5 weight percent; and less than about 95 weight percent, or less than about 80 weight percent, or less than about 50 weight percent of the total weight of the composition.

According to yet a further embodiment, the partially hydrolyzed fucoidan may be derived from Tongan limu moui, Japanese hoku kombu (Laminaria japonica); wakame, or mozuku (Cladosiphon and Nemacystus). In still a further embodiment, the partially hydrolyzed fucoidan may be sulfonated. Bases for Skin Care Compositions

Ideally, an ointment base should be nonirritating, nondehydrating, nongreasy, compatible with active ingredients, stable, easily removable with water, absorptive (able to absorb water and/or other liquids), and able to efficiently release the incorporated active ingredients. Ointments may be classified according to type, based on composition. Such ointment classes include oleaginous bases, absorption bases, emulsion bases, and water-soluble bases.

Oleaginous bases are generally anhydrous, hydrophobic, insoluble in water, and are not water- removable. Oleaginous bases includes the early ointments, which consisted almost entirely of vegetable and animal fats, as well as petroleum hydrocarbons. Fixed oils of vegetable origin include olive, cottonseed, sesame, persic, and other oils. Hydrocarbon bases include ointments prepared from petrolatum or liquid petrolatum with wax or other stiffening agents. Hydrocarbon bases do not become rancid, which is an advantage compared to animal fats and vegetable oils. Another oleaginous base includes silicones, which are synthetic polymers in which the basic structure is an alternating chain of silicon and oxygen atoms (e.g., -O- Si-O-Si-O-Si-). Silicones used in the pharmaceutical and cosmetic industries include dimethylpolysiloxane, methylphenylpolysiloxane, and a stearyl ester of dimethylpolysiloxane, all of which are insoluble in water and are water repellant. Illustrative oleaginous bases are well known in the art, such as Silicone Gibson Base (Example 2) and Vanisil Silicone Ointment (Example 3).

Absorption bases are generally anhydrous, hydrophilic, insoluble in water, and most are not water- removable. These bases have the property of absorbing several times their weight of water and forming emulsions while retaining their ointment-like consistency. Absorption bases vary in their composition, but for the greater part, they are mixtures of animal sterols with petrolatum. Combinations of cholesterol and/or other lanolin fractions with white petrolatum are such absorption bases, and Eucerin^® and Aquaphor^® (available from Beirsdorf Aktiengesellschaft Corporation, Germany) were among the earliest commercial bases of this type. Zopf Emollient Cream (Example 4), Hoch Formula (Example 5), Hydrophilic Petrolatum Base (Example 6), Wool Alcohols Base (Example 7), and Aquabase Ointment (Example 8) are absorption bases described herein. Some commercially available absorption bases include Aquafor^® (made by Duke Laboratories, South Norwalk, Connecticut), Polysorb^® (made by Fougera, a division of Altana Inc., Melville, New York), and Nivea^® Cream (made by Duke Laboratories, South Norwalk, Connecticut).

Emulsion bases may be either W/O bases, which are hydrous, insoluble in water, and not removable with water and will absorb water, or O/ W bases, which are hydrous, insoluble in water, and water-removable and will absorb water. These preparations are solid emulsions, and similar products have long been used as cosmetic creams. The availability of numerous compounds for use as wetting agents, dispersing agents, emulsifϊers, penetrants, emollients, detergents, hardeners, preservatives, and the like has given a great deal of flexibility to ointment formulation. Although surface-active agents (i.e., surfactants) may be ionic or noπionic, the nonioπic agents are widely used in dermatologic and pharmaceutical preparations. Polysorbate 80 (e.g., Tween.80) and Polyoxyl 40 Stearate represent such surfactants. Nonionic surfactants are generally less toxic and less irritating than ionic surfactants. Other advantages include their virtual neutrality, stability to freezing, stability to electrolytes, and ease of use. In general, the emulsion bases contain an aqueous phase, an emulsifying agent, and an oleaginous phase. The water phase of illustrative emulsion bases typically varies from 10 to 80% by weight of the total base. Glycerin, propylene glycol, or a polyethylene glycol is generally included with the aqueous phase to serve as a humectant, to reduce water loss through evaporation, and to lend a general softness to the creams. The addition of certain alcohols to emulsion base formulas also adds stability to the emulsion and imparts a smooth feel to the skin. Stearyl alcohol, a solid, increases the consistency of the ointment and permits the incorporation of more liquid components. Due to their ability to become hydrated, such alcohols assist in water retention of emulsion bases. The oleaginous phase may contain one or more of the following or similar ingredients: petrolatum, fats, waxes, organic alcohols, polyglycol esters, or other grease-like substances. These substances are emulsified with the aqueous phase through the action of the surfactant. A few such emulsifiers include alkali soaps, alkyl sulfates, amine soaps, polyglycol esters, alkyl aryl sulfates, quaternary ammonium compounds, and the like. These emulsifying compounds aid in the dispersion of the fats and waxes in water and increase the stability of the ointments. Hydrophilic Ointment Base (Example 1 1), Beeler's Base (Example 12), and U.C.H. Base (Example 13) are illustrative O/W emulsion bases described herein. Commercially available O/W emulsion bases include Cetaphil^® Cream (made by Galderma Laboratories, L.P., Princeton, New Jersey), Neobase (made by Neobase, Seattle, Washington), Unibase^® (made by Pfizer, New York, New York), Dermovan, Phorsix Cream, Lubriderm^® Cream (made by Pfizer, New York, New York), and Velvachol^® (available from Galderma Laboratories, Inc., Fort Worth, Texas).

Water-soluble bases are anhydrous, soluble in water, water-removable, and greaseless, and will absorb water. These bases include those bases prepared from polyethylene glycols as well as semisolid preparations containing bentonite, colloidal magnesium aluminum silicate, and sodium alginate. Polyethylene glycol (PEG) compounds 1500, 1540, 4000, and 6000 are of interest in ointment and lotion formulations. PEG 1500 is a soft waxy solid, similar in consistency to petrolatum, with a congealing range of 40⁰C to 45°C. PEG 1540 is a solid of consistency of beeswax and is intermediate in physical properties between the 1500 and 4000 PEGs. PEG 4000 has a congealing range of 53°C to 56⁰C and is most useful as a component of being an ointment base for, in addition to the general property of being an emulsifying and dispersing agent, it also adds to the consistency of the base. Both PEG 4000 and PEG 6000 are noTihygroscopic. PEG 6000 is a hard, translucent, waxy solid, and has a congealing range of 58°C to 62°C.

Glyceryl monostearate is a polyhydric alcohol ester that has been widely used in cosmetic and ointment bases. It has a high melting point (56°C to 58°C) and is a good emulsifying agent. Glyceryl monostearate emulsions generally contain high water phases, usually above 60% by weight. It has the disadvantage of being incompatible with acids. Glyceryl Monostearate Base (Example 23) is described herein.

Cellulose derivatives, such as methylcellulose and hydroxyethyl cellulose, form colloidal solutions that resemble gums and mucilages, but are not as vulnerable to fungal or bacterial attack. Methylcellulose is dispersible in cold water, but in concentrated solutions will coagulate upon heating. Hydroxyethyl cellulose is more soluble at elevated temperatures so that viscosity of aqueous solutions decreases slightly on warming. It is a good protective colloid for aqueous dispersions of oils, waxes, and pigments. Sodium carboxymethylcellulose is another cellulose derivative frequently referred to as carboxymethyl cellulose or CMC. It is an anionic compound and thereby can be used as a thickening or stabilizing agent for suspensions and for ointments of the emulsion type where the emulsifying agent is anionic or nonionic. Any of these cellulose derivatives can be used to stabilize ointment formulas, and they are commercially available in various viscosity types and with various degrees of substitution.

Sodium alginate is a hydrophilic colloid that is compatible with small amounts of alcohol, glycerin, polyglycols, wetting agents, and solutions of alkali carbonates. It functions satisfactorily under acid or alkaline conditions within the pH range of 4.5-10. It is possible to make sodium alginate solutions into semi- firm or firm gels by the addition of small amounts of soluble calcium salts, i.e., calcium gluconate, calcium tartrate, and calcium citrate. Ions of the alkaline earth metals will thicken or gelatinize sodium alginate solutions when present in low concentrations, while at high concentrations they will precipitate them. A 2.5% solution of sodium alginate is a satisfactory inert diluent for greaseless and other types of ointments. Bentonite, a colloidal hydrated aluminum silicate, is insoluble in water, but when mixed with 8 to

10 parts of water it swells to produce a slightly alkaline gel resembling petrolatum. The consistency of the product may be regulated by varying the amounts of water added. Ointments prepared from bentonite and water alone are found to be slightly drying and unstable upon standing, but addition of a humectant, such as glycerin or sorbitol, in amounts up to about 10% by weight will retard this action. Ointments prepared from bentonite do not encourage mold growth, and they have the advantage of not spreading to the hair when applied to the scalp.

Colloidal magnesium aluminum silicate (e.g., Veegum^®, R.T. Vanderbilt Company, Inc.) is an inorganic emulsifϊer, suspending agent, and thickener. Dispersions are slightly alkaline and are compatible with about 20 to 30% ethyl alcohol, isopropyl alcohol, acetone, and similar solvents. Glycols, such as glycerin and propylene glycol, are compatible at 40 to 50% concentrations.

Carbopol^® 934 (carboxypolymethylene, made by B. F. Goodrich Chemical Co., Akron, Ohio) is an acid polymer that disperses readily in water to yield an acid solution of low viscosity. When the acid solution is neutralized with a suitable base, such as sodium bicarbonate, sodium hydroxide, or the like, a clear, stable gel results. Carbopol^® 934 is inert physiologically and is neither a primary irritant nor a sensitizer. The thickening efficiency of Carbopol^® 934 may be used in the preparation of such pharmaceuticals as creams, ointments, lotions, suspensions, and emulsions. Anti- Wrinkle Compounds

The art of anti-wrinkle compounds is well-established with many compounds available for filling the role of anti-wrinkle. Specifically in this invention includes anti-wrinkle compounds for application to the exterior of the body, namely the skin. Though skin may appear to be flat, when viewed from a close position, the texture of the skin becomes visible. The texture consists of fine grooves (sulci cutis) surrounding parts (cristae cutis). The sulci cutis provide a corneum having low flexibility with capability to meet dynamic deformation, and they are a passage for sebum and sweat. The appearance of skin is affected by the texture of the skin. As the skin ages, it becomes more textured, coarsened and chapped. Further, diseases such as pustulosis, acne, eczema, psoriasis, lichen, ichthysis, keratosis, and atopic dermatitis bring about change in the appearance and function of the skin.

Various chemicals, ointments, creams, compounds, vitamins, and so forth have been used to ameliorate the texture of the skin, or to prevent and/or heal wrinkles. Exemplary anti-wrinkle compounds suitable for use in the compositions of the present invention include hydroxy acids (e.g., salicylic acid, glycolic acid), keto acids (e.g., pyruvic acid), ascorbic acid (vitamin C) and its derivatives, phytic acid, lysophosphatidic acid, flavonoids (e.g., isoflavones, flavones, etc.), stilbenes, cinnamates, resveratrol, kinetin, zeatin, dimethylaminoethanol, peptides from natural sources (e.g., soy peptides), salts of sugar acids (e.g., Mn gluconate), and retinoids which enhance the keratinous tissue appearance benefits of the present invention, especially in regulating keratinous tissue condition, e.g., skin condition, and other vitamin B compounds (e. g., thiamine (vitamin Bl), pantothenic acid (vitamin B5), carnitine (vitamin Bt), riboflavin (vitamin B2), and their derivatives and salts (e. g., HCl salts or calcium salts)), and other compounds as herein described. These may be in their natural form or in a synthetically produced form. These may be purified or used in an impure state. Another type of compound to use as an anti-wrinkle compound include substances having an epithelium-abrasive action such as α-hydroxy acids including lactic acid and glycolic acid and β-hydroxy acids represented by salicylic acid. Also amino acids, polyhydric alcohols, polysaccharides, and lipids such as ceramides may be used.

In one illustrative embodiment, the present composition includes antioxidants. The amount of antioxidants of the present invention may be from about 0.01 weight percent to about 10 weight percent.

Some examples of antioxidants may include tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, 6-hydroxy-2,5,7,8-tetramethylchroman -2 -carboxylic acid (commercially available under the trademark Trolox®), amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), nordihydroguaiaretic acid, bioflavonoids, amino acids, silymarin, and the like. Some sources of antioxidants or oxidant scavengers include tea extracts, and grape skin/seed extracts may be used.

In one illustrative embodiment, the composition of the present invention includes dehydroacetic acid, its isomers, derivatives, tautomers, or pharmaceutically acceptable salts thereof. As used herein, "pharmaceutically acceptable" means that the salts of dehydroacetic acid are suitable for use in contact with the tissues of mammals to which they will be exposed without undue toxicity, incompatibility, instability, irritation, allergic response, and the like. The technical name for dehydroacetic acid is 3-acetyl-6-methyl- 2H-pyran-2,4(3H)-dione and can be commercially purchased from Lonza Group, Ltd. of Basel, Switzerland. Pharmaceutically acceptable salts include alkali metal salts, such as sodium and potassium; alkaline earth metal salts, such as calcium and magnesium; non-toxic heavy metal salts; ammonium salts; and trialkylammonium salts, such astrimethylammonium and triethylammonium. Sodium, potassium, and ammonium salts of dehydroacetic acid are useful. Highly useful is sodium dehydroacetate which can be purchased from Tri-K, as Tristat SDHA. Derivatives of dehydroacetic acid include, but are not limited to, any compounds wherein the CH₃ groups are individually or in combination replaced by amides, esters, amino groups, alkyls, and alcohol esters. Tautomers of dehydroacetic acid are the isomers of dehydroacetic acid which can change into one another with great ease so that they ordinarily exist in equilibrium. Thus, tautomers of dehydroacetic acid can be described as having the chemical formula C₈H₈O₄ and generally having the structure above. Radiation Protecting Agent

The radiation protecting agent may be any that is known in the art of sunblocks or sunscreens. Some of the major types of radiation protecting agents include physical blockers, and chemical protectants. Physical blockers work by physically blocking the solar radiation from reaching the skin. Some examples of theses physical blockers include titanium dioxide, aluminum oxide, magnesium dioxide, and zinc oxide, with titanium dioxide and zinc oxide being the most used in conventional sunblocks. Physical blockers typically block both UV-A and UV-B radiation from reaching the skin. Chemical protectants include organic molecules with carbonyl groups. Some examples of chemical protectants include, for example, /7-aminobenzoic acid (PABA), its salts and its derivatives (ethyl, isobutyl, glyceryl esters; p-dimethylaminobenzoic acid), anthranilates (i.e., o-aminobenzoates; 5, methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terpinyl, and cyclohexenyl esters), salicylates (amyl, phenyl, benzyl, octyl, menthyl, glyceryl, and dipropyleneglycol esters), trolamine salicylate, avobenzone, cinnamic acid derivatives (methyl and benzyl esters, a-phenyl cinnamonitrile; butyl cinnamoyl pyruvate), cinoxate, dihydroxycinnamic acid derivatives (umbel liferone, methylumbelliferone, methylaceto-umbelliferone), trihydroxycinnamic acid derivatives (esculetin, methylesculetin, daphnetin, and the glucosides, esculin and daphnin), hydrocarbons (diphenylbutadiene, stilbene), dibenzalacetone, benzalacetophenone, dioxybenzone, naphtholsulfonates (sodium salts of 2 -naphthol- 3,6-disulfonic and of 2-naphthol-6,8-disulfonic acids), dihydroxy-naphthoic acid and its salts, o- and/?- hydroxybiphenyidisulfonates, homosalate, menthyl anthranϊlate, coumarin derivatives (7-hydroxy, 7-methyI, 3-phenyl), octyl methoxyciπnamate (octinoxate), diazoles (2-acetyl-3-bromoindazole, phenyl benzoxazole, methyl naphthoxazole, various aryl benzothiazoles), quinine salts (bisulfate, sulfate, chloride, oleate, and tannate), quinoline derivatives (8- hydroxyquinoline salts, 2-phenylquinoline), hydroxy- or methoxy-substituted benzophenones, uric and vilouric acids, tannic acid and its derivatives (e.g., hexaethylether), (butyl carbotol) (6-propyl piperonyl) ether, hydroquinone, oxybenzone, padimate-o, phenylbenzimidazole sulfonic acid, benzophenones (oxybenzene, sulisobenzone, dioxybenzone, 2,2',4,4'-tetrahydroxybenzophenone, 2,2'-dihydroxy-4,4'- benzoresorcinol, dimethoxybenzophenone, octabenzone), aminobenzoic acid, 4-isoρropyldibenzoyl methane, butyl methoxydibenzoyl methane, etocrylene, 4-isopropyl-di-benzoylmethane, 2-ethyl hexyl-p- methoxycinnamate (commercially available as PARSOL MCX), 4,4'-f-butyl methoxydibenzoyl- methane (commercially available as PARSOL 1789), 2 -hydroxy-4-methoxybenzophenone, octyldimethyl-p- aminobenzoic acid, digalloyltrioleate, 2,2-dihydroxy-4-methoxybenzophenone, ethyl-4-(bis(hydroxy- propyl))aminobenzoate, 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, 2-ethylhexyl-salicylate, glyceryl-p- aminobenzoate, 3,3,5-tri- methylcyclohexyl salicylate, methylanthranilate,/?-dimethyl-arntnobenzoic acid or aminobenzoate, 2-ethylhexyl-p-dimethylaminobenzoate, 2-phenyIbenzimidazole-5-sulfonic acid, 2-(p- dimethylaminopheπyl)-S-sulfonicbenzoxazoic acid, ensulizole, meradimate, and mixtures thereof. Many of these chemicals are regulated by the Food and Drug Administration as to the maximum amount that may be present in the composition for application to the hair or skin. For example, PABA is regulated such that the composition must not include more than 15% PABA. Further, many of the chemical protectants only protect against UV-A or UV-B. Some protect against both UV-A an UV-B, such as dioxybenzone, oxybenzone, and sulisobenzone. Optional Components

In one illustrative embodiment, the present composition includes flavonoids. Flavonoids may be incorporated in the skin care composition in the amount of from about 0.01 to about 20 weight percent. Flavaπones such as unsubstituted flavanones, mono- substituted flavanones, and mixtures thereof; chalcones selected from unsubstituted chalcones, mono-substituted chalcones, di-substituted chalcones, tri-substituted chalcones, and mixtures thereof; flavones selected from unsubstituted flavones, mono-substituted flavones, di-substituted flavones, and mixtures thereof; one or more isoflavones; coumarins selected from unsubstituted coumarins, mono-substituted coumarins, di-substituted coumarins, and mixtures thereof; chromones selected from unsubstituted chromones, mono-substituted chromones, di- substituted chromones, and mixtures thereof; one or more dicoumarols; one or more chromanones; one or more chromanols; isomers (e.g., cis/trans isomers) thereof; and mixtures thereof. By the term "substituted" as used herein means flavonoids wherein one or more hydrogen atom of the flavonoid has been independently replaced with hydroxyl, C1-C8 alkyl, C1-C4 alkoxyl, O-glycoside, and the like or a mixture of these substituents. Examples of suitable flavonoids include, but are not limited to, unsubstituted flavanone, mono-hydroxy flavanones (e.g., 2'-hydroxy flavanone, 6-hydroxy flavanone, 7-hydroxy flavanone, etc.), mono-alkoxy flavanones (e.g., 5-methoxy flavanone, 6-methoxy flavanone, 7-methoxy flavanone, 4'-methoxy flavanone, etc.), unsubstituted chalcone (especially unsubstituted trans-chalcone), mono-hydroxy chatcones (e.g., T- hydroxy chalcone, 4'-hydroxy chalcone, etc.), di-hydroxy chalcones (e.g., 2',4-dihydroxy chalcone, 2,4'- dihydroxy chalcone, 2,2'-dihydroxy chalcone, 2',3-dihydroxy chalcone, 2',5'-dihydroxy chalcone, etc.), and tri-hydroxy chalcones (e.g., 2',3',4-trihydroxy chalcone, 4,2',4'- trihydroxy chalcone, 2,2',4-trihydroxy chalcone, etc.), unsubstituted flavone, 7,2'-dihydroxy flavone, 3',4'-dihydroxy naphthoflavone, 4'- hydroxy flavone, 5,6-benzoflavone, and 7,8-benzoflavone, unsubstituted isoflavone, daidzein (7,4'-dihydroxy isofiavone), 5,7-dihydroxy-4'- methoxy isoflavone, soy isoflavones (a mixture extracted from soy), unsubstituted coumarin, 4-hydroxy coumarin, 7-hydroxy coumarin, 6-hydroxy-4-methyl coumarin, unsubstituted chromone, 3-formyl chromone, 3-forrnyl-6- isopropyl chromone, unsubstituted dicoumarol, unsubstituted chromanone, unsubstituted chromanol, and mixtures thereof.

In another illustrative embodiment, the composition may include conditioning agents. Conditioning agents of the present embodiment may include humectants, moisturizers, skin conditioners, and so forth. The amount of these conditioning agents may be from about 0.01 weight percent to about 20 weight percent. The conditioning agents may include, for example, guanidine; urea; glycolic acid and glycolate salts (e.g. ammonium and quaternary alkyl ammonium); salicylic acid; lactic acid and lactate salts (e.g., ammonium and quaternary alky] ammonium); aloe vera in any of its variety of forms (e.g., aloe vera gel); polyhydroxy alcohols such as sorbitol, mannitol, xylitol, erythritol, glycerol, hexanetriol, butanetriol, propylene glycol, butylene glycol, hexylene glycol and the like; polyethylene glycols; sugars (e.g., melibiose) and starches; sugar and starch derivatives (e.g., alkoxylated glucose, fiicose); hyaluronic acid; lactamide monoethanolamine; acetamide monoethanolamine; panthenol; allantoin; and mixtures thereof.

Further, components formulated to improve the collagen and/or elastin of the skin may be added. U.S. Patent No. 6,641,848 discloses formulas for increasing collagen IV. Collagen is a major constituent of the junction between the dermis and the epidermis. Certain compounds have been found to strengthen this junction, which is required for proper functioning of the skin. Some of these compounds include, for example, triterpenic saponins and sapogenols. Saponins or sapogenols may be extracted from plants, such as Glycine max (soya), Phaseolus vulgaris, Phaseolus aureaus, Phaseolus lunatus, Viciafaba, Lens culinaris, Cicer arietum, Vigna angulaήs, Vigna mungo, Oxytropis ochrocephala, Oxytropis glabra, Pisum sativum, Sophora favescens, Asparalus membranaceiis, Crotalaria albida, Arachis hypogea, Galega officinalis, Wistaria brachybotrγs, and Trifolium repens, or those extracted from plants of the Medicago type, particularly Medicago alfalfa and Medicago sativa, which is often called "alfalfa." In another example, hydroxyprofisiland-C may be added.

According to yet another embodiment of the present invention, the skin care composition includes antimicrobial and/or antifungal compounds. The amount of these compounds in the skin care composition may be from about 0.001 to about 10 weight percent. Some suitable antimicrobial /antifungal compounds may include, for example, benzoyl peroxide, 3-hydroxy benzoic acid, glycolic acid, lactic acid, 4-hydroxy benzoic acid, 2-hydroxybutanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, phytic acid, Iipoic acid, azelaic acid, arachidonic acid, benzoylperoxide, tetracycline, ibuprofen, naproxen, hydrocortisone, acetaminophen, resorcinol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'-trichloro-2'- hydroxy diphenyl ether, 3,4,4'-trichIorocarbanilide, octopirox, ciclopirox, lidocaine hydrochloride, clotrimazole, miconazole, ketoconazole, neocycin sulfate, and mixtures thereof.

Some other useful natural components that may be used include, for example, witch hazel, mangosteen, honey, aloe, sage, piper, clove, ginger, red pepper, willow, rhubarb, sesame, chamomile, propolis, thyme, lavender, cinnamon oil, flower or blossom oils, olive oil, palm oil, coconut oil, beeswax, and so forth. One particularly beneficial natural component is a derivative of the mangosteen plant. According to one embodiment, the present invention includes from about 0.01 to about 10 weight percent of a derivative of the mangosteen plant.

The mangosteen plant (Garcinia mangostana L.) is a tropical fruit-bearing plant named after the French explorer, Laurent Garcin. Many of the benefits of the mangosteen plant and its derivatives are described in U.S. Patent No. 6,730,333. Over the years, the mangosteen plant has been used in a number of different ways. The timber is used for cabinets, building materials, fencing and furniture. The pericarp, containing pectin, tannins, resins and a yellow latex, is used in tanning and dyeing leather black. The fruit pulp is mostly used as a dessert, but can also be canned or made into preserves. However, when removing the fruit pulp from the rind, care must be taken to prevent the tannins and resins of the cut pericarp from contacting the fruit pulp. The mangosteen rind, leaves and bark have also been used as components in folk medicine in areas where the plant grows indigenously. The thick mangosteen rind is used for treating catarrh, cystitis, diarrhea, dysentery, eczema, fever, intestinal ailments, itch, and skin ailments. The mangosteen leaves arc used by some natives in teas and other decoctions for diarrhea, dysentery, fever, and thrush. It is also known that concoctions of mangosteen bark can be used for genitourinary afflictions and stomatosis.

Some of the medicinal properties of the Garcinia mangostana L . plant have been the subject of pharmacological and clinical studies. These studies have isolated chemical constituents in- the mangosteen leaves, wood, pericarp and seed aril, which were found to contain the following biologically active compounds, among others: 1 ,6-dihydroxy-3- methoxy-2-(3-methyl-2-butenyl) xanthone, l,5,8-trihydroxy-3- methoxy-2-(3- methyl-2-butenyl) xanthone, maclurin, I 3,6,7-tetrahydroxy xanthone, 1 3, 6,7-tetrahydroxy xanthone-O-β-D-glucoside, chrysanthemin, cyaniding-3- O-β-D-sophoroside, 8-deoxygartanin, l,5- dihydroxy-2-isopentenyl-3- methoxy xanthone, l,7-dihydroxy-2-ϊsopentenyl-3-methoxy xanthone, 5,9- dihydroxy-S-methoxy-2,2-dimethyI-7-(3-methylbut-2-enyl)2(H), 6(H)-pyraπo- (3,2,6)-xanthen-6-one, fructose, garcinone A,B,C, D and E₃ gartanin, glucose, cis-hex-3-enyl acetate, 3-isomangostin, 3- isomangostin hydrate, 1-isomangostin, 1-isomangostin hydrate, kolanone, mangostin, β-mangostin, α- mangostin, mangostin-3,6-di-O-glucoside, πormangostin, sucrose, tannins, BR-xanthone-A, BR-xanthone-B, calabaxanthone demethylcalabaxanthone, 2-(γ,γ-dimethylallyl)-I,7-dihydroxy-3- methoxyxanthone, 2,8-bis- (γ,γ-dimethylally])-l 3,7- trihydroxyxanthone, 1, 3,5,8-tetrahydroxy-2,4-diprenylxanthone, and mangostanol. Many of these chemical constituents are xanthones, which are biologically active compounds that are receiving increasing interest in pharmacological studies for a variety of health benefits.

The skin care compositions of the present invention may also contain fragrances, proteins, colorants or coloring agents, vitamins, botanical extracts, lipids, glycolipids, polymers, and copolymers, and the like, as are generally known in the art of making skin care products. The Cosmetic, Toiletry, and Fragrance Association's'International Cosmetic Ingredient Dictionary and Handbook is an excellent source of information concerning such ingredients.

As used herein, "colorants" or "coloring agents" are agents that give skin care compositions a more pleasing appearance, and in addition help the manufacturer to control the product during its preparation and help the user to identify the product. Any of the approved certified water-soluble FD&C dyes, mixtures thereof, or their corresponding lakes may be used to color skin care compositions. A color lake is the combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye.

The skin care compositions of the present invention may include an. analgesic. Analgesics are typically used to assist in the alleviation of pain. Some examples of the analgesics than may be included in the present skin care composition include, but are not limited to, hydrocortisone, hydroxyltriamcinolone, alpha-methyl dexamethasone, dexamethasone- phosphate, beclomethasone dipropionate, clobetasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortine butylester, fluocortolone, fluprednidene (fluprednylidene) acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenolone acetonide, medrysone, amcinafel, arncinafϊde, betamethasone and the balance of its esters, chloroprednisone, chlorprednisone acetate, clocortelone, clescinolone, dichlorisone, difluprednate, flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone cyclopentylpropionate, hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, triamcinolone, piroxicam, isoxicam, tenoxicam, sudoxicam, CP-14,304, aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal, diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepiract, clidanac, oxepinac, and felbinac, mefenamic, meclofenamic, flufenamic, niflumic, and tolfenamic acid, ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic, phenybutezone, oxyphenbutezone, feprazone, azapropezone, and trimethazone and mixtures thereof.

The skin care compositions of the present invention may include antioxidant or radical scavengers. Suitable anti-oxidants or radical scavengers include, but are not limited to, butylated hydroxy benzoic acids, ό-hydroxy^SJ.S-tetramethylchroman^-carboxylic acid, gallic acid, propyl gallate, uric acid, sorbic acid, ascorbyl esters of fatty acids, amines, sulfhydryl compounds, dihydroxy fumaric acid, pharmaceutically acceptable salts thereof, alkyl esters thereof, derivatives thereof and mixtures thereof.

The skin care compositions of the present invention may include topically administered vitamins. Such vitamins include, but are not limited to Vitamin A, ascorbic acid, Vitamin B, biotin, pantothenic acid, Vitamin D, Vitamin E and mixtures thereof and derivatives thereof. Derivatives or analogs of these vitamins may also be used such as synthetic Vitamin A analogs, natural Vitamin A analogs, geometric isomers and stereoisomers and mixtures thereof.

The skin care composition may include propellants. Propellants may include propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide.

The composition may also include solvents such as, for example, SD alcohol 40, ethyl alcohol, methylene chloride, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxide, dimethyl formamide, tetrahydrofuran.

The skin care composition may include powders, such as chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica sodium polyacrylate, terra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate.

The skin care compositions of the present invention are applied to the skin in amounts selected by the user. The compositions are dispensed from appropriate containers and are generally manually applied to the skin, as is well known in the art. Substrates for Article

An illustrative embodiment of the present invention is useful with tissue paper in general, including but not limited to conventionally felt-pressed tissue paper; high bulk pattern densified tissue paper; and high bulk, uncompacted tissue paper. It can be of a homogenous or multi-layered construction; and tissue paper products made therefrom can be of a single-ply or multi-ply construction. The tissue paper can have a basis weight of between about 10 g/πr and 130 g/m², or between about 20 g/πr and 80 g/nr or between about 25 g/nr and 60 g/m². Unless otherwise specified, all amounts and weights relative to the paper are on a dry basis.

The tissue of the present invention comprises at least one fibrous ply and may include two or more fibrous plies. The fibrous ply may be noncellulosic, or cellulosic, or a combination thereof. The fibrous ply may be layered. Each fibrous ply has two sides. Side one of the fibrous ply is generally oriented toward the user while side two of the fibrous ply is generally oriented away from the user. A base and partially hydrolyzed fucoidan according to the present invention can be applied to one or more of the fibrous plies. The base and partially hydrolyzed fucoidan may be applied to side one of the fibrous ply, side two of the fibrous ply, or both sides.

Conventionally pressed tissue paper and methods for making such paper are well known in the art. Such paper is typically made by depositing a papermaking furnish on a foraminous forming wire, often referred to in the art as a fourdrinier wire. Once the furnish is deposited on the forming wire, it is referred to as a web. The web is dewatered by pressing the web and drying at elevated temperature. The particular techniques and typical equipment for making webs according to the process just described are well known to those skilled in the art. Anti-Viral Agents

The tissue of the article-containing embodiment of the present invention may also include anti-viral agents. Certain viral infections are spread through bodily secretions. It is, therefore, an advantage to include anti-viral agents which neutralize viruses in a tissue that may be used to wipe or adsorb bodily secretions. U.S. Patent No. 6,517,849discloses the addition of certain anti-viral agents to tissues.

The antiviral agent of the present invention may comprises pyrrolidone carboxylic acid. Pyrrolidone carboxylic acid, which is also referred to as pyroglutamic acid, has two stereoisomers (D and L). Both stereoisomers are suitable for use in the present invention. Each or mixtures thereof are for use herein. Furthermore, blends of the two stereoisomers may also be used. The L stereoisomer is useful.

The D stereoisomer of pyroglutamic acid is also known by the following names: D-Proline, 5-oxo- (+)-2-Pyrrolidone-5-carboxylic acid, (+)-Pyrog!utamic acid, (R)-2-Pyrrolidone-S-carboxylic acid, 5-Oxo-D- proline, D-2-Pyrrolidone-5-carboxylic acid, D-Pyroglutamic acid, D-Pyrrolidinonecarboxylic acid, and D- Pyrrolidonecarboxylic acid. The L stereoisomer of pyroglutamic acid is also known by the following names: L-Proline, 5-oxo-(-

)-2-Pyrro1idone-5-carboxylic acid, (-)-Pyroglutamic acid, (SS)-2-Oxopyrrolidine-5-carboxyIic acid, (S)-(-)-2- Pyrrolidone-5-carboxylic acid, (S)-2-Pyrrolidone-5-carboxylic acid, (S)-5-Oxo-2-pyrroIidinecarboxyIic acid, (S)-Pyroglutamic acid, 2-L-Pyrrolidone-5-carboxylic acid, 2 -Pyrrolidinone-5-carboxyIic acid, 5-Carboxy-2- pyrrolidmone, 5-Oxo-L-proline, 5-Oxoproline, S-PyrroIidinone^-carboxylic acid, Glutimic acid, Glutiminic acid, L^-Pyrrolidone-S-carboxylic acid, L-5-Carboxy-2-pyrrolidinone, L-S-Oxo-2-pyrrolidinecarboxylic acid, L-5-OxoproIine, L-Glutamic acid, gamma-lactam, L-GIutimic acid, L-Glutiminic acid, L-Pyroglutamic acid, L-Pyrrolidinonecarboxylic acid, L-Pyrrolidonecarboxylic acid, Oxoproline, PCA, Pidolic acid, Pyroglutamic acid, PyrrolidinonecarboxylJc acid, Pyrrolidone-5-carboxyIic acid, and Pyrrolidonecarboxylic acid. The DL form of pyroglutamic acid (a mixture of the D and L stereoisomers) is known by the following names: DL-Proline, 5-oxo-(+-)-2-Pyrrolidone-5-carboxylic acid, (+-)-Pyroglutamic acid, 5-Oxo- DL-proline, DL-2 -PyiTolidinone-5-carboxylic acid, DL-2-Pyrro!idone-5-carboxylic acid, DL-Pyroglutamate, DL-Pyroglutamic acid, DL-Pyrrolidonecarboxylic acid, and Oxoproline. The DL form is also commercially available under the trade name Aj idew™ A 100.

In addition to pyrrolidone carboxylic acid, other organic acids may be optionally added to the antiviral composition. These include but are not limited to organic acids such as ascorbic acid and other carboxylic acids.

Suitable other carboxylic acids include but are not limited to alpha hydroxy acids such as Cl to C12 saturated, unsaturated, or mixtures thereof of carboxylic acids possessing 1 to 4 carboxylic acid groups and having at least one hydroxyl group substituted on the C2 alpha carbon with additional hydroxy! and other functionalities (i.e.; phenyl, amino, alkyl, etc.) optionally bound along the carbon chain and aromatic ring(s). A non-inclusive list of alpha hydroxy acids which may be used includes: 2-hydroxyhexanoic acid, 2- hydroxyoctanoic acid, 2-hydroxydecanoic acid, 2-hydroxydodecanoic acid, 2-hydroxycaprylic acid, citric acid, tartaric acid, mandelic acid, malic acid, glycolic acid, lactic acid, gluconic acid, hydroxycaprylic acid, 2-hydroxypropionic acid, 2-hydroxybutanoic acid, 2-hydroxypentanoic acid, and mixtures thereof.

Other examples of carboxylic acids useful with this invention include beta hydroxy acids such as Cl to C12 saturated, unsaturated, aromatic, or mixtures thereof of carboxylic acids possessing 1 to 4 carboxylic acid groups and having at least one hydroxyl group substituted on the C3 beta carbon with additional hydroxyl and other functionalities (i.e.; phenyl, amino, hydroxyl, alkyl, etc.) optionally bound along the carbon chain or aromatic ring(s). A non-inclusive list of beta hydroxy acids useful with this invention includes: 3-hydroxyhexanoic acid, 3-hydroxyoctanoic acid, 3-hydroxydecanoic acid, 3-hydroxydodecanoic acid, 3 -hydroxycaprylic acid, salicylic acid, 5-octanoyl salicylic acid, 3-hydroxybutanoic acid, 3- hydroxypentanoic acid, 3-hydroxypropionic acid, and mixtures thereof. A non-inclusive list of other carboxylic acids useful with this invention includes Cl to Cl 2 saturated, unsaturated, aromatic, or mixtures thereof of carboxylic acids possessing 1 to 4 carboxylic acid groups with optional functional groups (i.e.; phenyl, amino, hydroxyl, alkyl, etc.) substituted along the carbon chain or on the aromatic ring(s) such as propionic acid, hexanoic acid, octanoic acid, decanoic acid; Cl to C12 carboxylic acids possessing 1 to 4 carboxylic acid groups wherein a hydroxyl group(s) is substituted on carbon number(s) C4 or above such as 4-hydroxyhexanoic acid, 5,6-dihydroxyhexanoic acid, 6-hydroxyhexanoic acid, 4-hydroxyoctanoic acid, 5-hydroxyoctanoic acid, 6-hydroxyoctanoic acid, 6,7,8- trihydroxyoctanoic acid, 8-hydroxyoctanoic acid, 4-hydroxydecanoic acid, 5-hydroxydecanoic acid, 6- hydroxydecanoic acid, 7-hydroxydecanoic acid, 8-hydroxydecanoic acid, 9-hydroxydecanoic acid, 10- hydroxydecanoic acid, 4-hydroxydodecanoic acid, 5-hydroxydodecanoic acid, 6-hydroxydodecanoic acid, 11-hydroxydodecanoic acid, and 12-hydroxydodecanoic acid; benzoic acid; phthalic acid; acetylsalicylic acid; dehydroacetic acid; sorbic acid; succinic acid; glutaric acid; adipic acid; sebacic acid; maleic acid; folic acid; acetic acid; ethylenediaminetetraacetic acid; glycolic acid; and mixtures thereof.

Metal salts may also be used as an optional component of the antiviral agent of the present invention. Suitable metal salts include, but are not limited to, salts of metals selected from the groups consisting of Groups I(A, B), H(A, B), HlA, IV(A, B), VIB, VIII, rare earth compounds, and combinations thereof. Metal salts may include salts of metals selected from the group consisting of Mn, Ag, Zn, Sn, Fe, Cu, Al, Ni, Co, Ti, Zr, Cr, La, Bi, K, Cd, Yb, Dy, Nd, Ce, TI, Pr, and combinations thereof. Even more useful, metal salts include salts of metals selected from the group consisting of Mn, Ag. Zn, Sn, Fe, Cu, Al, Ni, Co, Ti, Zr, Cr₃ La, and combinations thereof. The metal salts may include salts of metals selected from the group consisting of Cu, Fe, and combinations thereof.

More particularly, the metal salts include, but are not limited to, dermatologically acceptable metal chelates and salts like bishistidine complexes, bromides, chondroitin sulfate, chromites, cyanides, dipicolinates, ethyl hexanoate s, glycerolate complex, methoxides, polyphosphonates, paraphenolsulfonates, perchlorates, phenolsulfonates, selεnides, stearates, thiocyanates, tripolyphosphates, tungstates, phosphates, carbonates, para-aminobenzoate, para-dimethylaminobenzoates, hydroxides, para-metboxycinnamate, naphthenates, stearates, caprates, laurates, myristates, palmitates, oleates, picolinates, pyrithiones, fluorides, aspartates, gluconates, iodides, oxides, nitrites, nitrates, phosphates, pyrophosphates, sulfides, mercaptopyridine-oxides (e.g., zinc pyrithione), nicotinates, and nicotinamides, hinokitiol, acetates, ascorbates, chlorides, benzoates, citrates, fumarates, gluconates, glutarates, lactates, malates, malonates, salicylates, succinates, sulfates, undecylates, and combinations thereof.

The tissue may include any number of optional ingredients that are known in the art of skin moisturizing. For example, a well-known herb used for skin healing is aloe. Aloe includes the juice of the leaves of any of the more than 240 species of aloe, or combinations thereof. Aloe with particular nutritional value comes from the Aloe barbadensis. The Aloe barbadensis with the most recognized nutritional value is the Aloe barbadensis Miller. Aloe has been used in topical and internal uses. In one embodiment, the aloe present in the composition includes powdered aloe. Commercial sources of the dry powdered aloe of the present invention are available, for example, from Aloe Laboratories, Harlingen, Texas, and NHK Laboratories, Santa Fe Springs, California. Method of Treating the Tissue In preparing virucidal tissue products according to the present invention, the base and the partially hydrolyzed fucoidan, along with the optional ingredients such as the antiviral composition may be applied to at least one surface of a tissue paper web. They may be applied uniformly or discretely to the tissue paper web. A non-limiting example of discrete addition to the tissue paper web is disclosed in U.S. Patent No. 5,814,188. The base, partially hydrolyzed fucoidan, and other optional ingredients may be applied in a continuous pattern or discontinuous pattern. Suitable application methods include those disclosed in U.S. Patent No. 4,481,243; U.S. Patent No. 5,720,966; and U.S. Patent No. 5,814,188.

Suitable methods include spraying, dipping, soaking, printing (e.g., flexographic printing), coating (e.g., gravure coating), extrusion, or combinations of these application techniques, e.g. spraying the composition on a rotating surface, such as a calendar roll, that then transfers the composition to the surface of the paper web. The composition can be applied either to one surface of the tissue paper web, or both surfaces.

The compositions of this invention can also be applied non-uniformly to the surface(s) of the tissue paper web. By "non-uniform" is meant that the amount, pattern of distribution, etc. of the antiviral agent can vary over the surface of the paper. For example, some portions of the surface of the tissue paper web can have greater or lesser amounts of the composition, including portions of the surface that do not have any composition on it.

An example of non-uniform application is where the tissue structure contains differing amounts and differing compositions of various formulations throughout its structure or alternatively where some zones may contain no lotion at all as taught by U.S. Patent No. 4,481,243.

Partially hydrolyzed fucoidan, and other optional ingredients are applied to the tissue. The tissue may include from about 0.05 to about 50 weight percent partially hydrolyzed fucoidan.

Examples

The following are examples of the preparation of seaweed to provide a fucoidan puree for use in skin care products, and skin care formulations prepared from the fucoidan puree. These examples are merely illustrative and are not meant to be limiting in any way.

The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims, rather than by the description or examples. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Example 1 Preparation of fucoidan puree composition

Tongan limu moui seaweed is manually harvested, cleaned to remove extraneous material, frozen, and shipped to a processing plant. At the plant, the frozen seaweed is thawed, weighed, and placed in a stainless steel mixer with aqueous buffer and optionally sulfuric acid according to any of the sets of conditions set out in Table 1. The ingredients are then mixed at 50-75 rpm with a medium shear mixer (propeller type). While mixing, the mixture is heated to 37°C to 95°C for a selected period of time (usually 5 min to 8 hr). At that point, heating is discontinued, but mixing is continued for 0.5-10 hours to dissipate heat and micronize the seaweed strands. The cooled mixture is then filtered to remove insoluble material, and the filtrate is covered and mixed at room temperature for about 4-72 hours. The pH of the resulting puree is determined to be about pH 2.0 to 4.0, and refractometry typically shows a Brix value of 2-4. The puree comprising partially hydrolyzed fucoidan is then frozen and stored. If sulfuric acid is added during hydrolysis, the partially hydrolyzed fucoidan is sulfonated.

Example 2 Silicone Gibson Base

The following formula illustrates a silicone base that may be used in a cream or lotion according to the present invention. Silicone Gibson base comprises 15 parts by weight of cetyl alcohol, 1 parts by weight of sodium laury! sulfate, 40 parts by weight of dimethylpolysiloxane polymer (1000 cps), 43 parts by weight purified water, 0.25 parts by weight methylparaben, and 0.15 parts by weight propylparaben. The aqueous mixture of the sodium lauryl sulfate and the parabens is warmed to 75⁰C, and then it is slowly added to warmed (25°C) cetyl alcohol-silicone mixture. The resulting mixture is stirred until it congeals.

Example 3 Vanisil Silicone Ointment Base

The following formula illustrates a silicone base that may be used in a cream or lotion according to the present invention. Vanisil silicone ointment base comprises 10 parts by weight stearic acid, 2 parts by weight synthetic Japan wax, 20 parts by weight dimethylpolysiloxane polymer (1000 cps), 0.5 parts by weight potassium hydroxide, 0.025 parts by weight methylparaben, 0.015 parts by weight propylparaben, and 67.5 parts by weight distil led water.

Example 4 Zopt Emollient Cream

The following formula illustrates a W/O emulsion absorption base that may be used according to the present invention. Zopf emollient cream comprises 41 parts by weight of white petrolatum, 3 parts by weight of microcrystalline wax, 10 parts by weight of fluid lanolin, 4.75 parts by weight sorbitan monooleate, 0.25 parts by weight of polysorbate 80, and 41 parts by weight purified water. The aqueous dispersion of sorbitan monooleate and polysorbate 80 is warmed to 75°C and then slowly added to the melted wax, white petrolatum, and fluid lanolin. The resulting mixture is stirred until it congeals.

Example 5 Hoch Formula

The following formula illustrates an O/W emulsion absorption base that may be used according to the present invention. Hoch formula comprises phase A comprising 5 parts by weight of fluid lanolin, 35 parts by weight of castor oil, 2 parts by weight of sorbitan monostearate, 36.7 parts by weight of mineral oil, 4 parts by weight of stearic acid, and 0.2 parts by weight of propylparaben; and phase B comprising 1 parts by weight of polyethylene 20 sorbitan monostearate, 0.9 parts by weight of triethanolamine, 0.2 parts by weight of methylparaben, and 15 parts by weight of purified water. Phase A is heated to 78°C, and phase B is heated to 70⁰C. Then, phase B is added to phase A and the resulting mixture is stirred until it cools to 25°C.

Example 6 Hvdrophilic Petrolatum Base

The following formula illustrates an absorption base that may be used according to the present invention. Hydrophilic petrolatum base comprises 30 parts by weight of cholesterol, 30 parts by weight of stearyl alcohol, 80 parts by weight of white wax, and 860 parts by weight of white petrolatum. The stearyl alcohol, white wax, and white petrolatum are melted together on a steam bath, and then the cholesterol is added and stirred into the mixture until the cholesterol completely dissolves. The mixture is then removed from the bath and stirred until it congeals. Example 7 Wool Alcohols Base

The following formula illustrates an absorption base that may be used according to the present invention. Wool alcohols ointment base comprises 60 parts by weight wool alcohols, 240 parts by weight hard paraffin, 100 parts by weight white or yellow soft paraffin, and 600 parts by weight liquid paraffin. The ingredients are mixed together and stirred until cold.

Example 8 Aouabase Ointment

The following formula illustrates an absorption base that may be used according to the present invention. Aquabase ointment comprises 30 parts by weight of cholesterol, 30 parts by weight of cottonseed oil, and 940 parts by weight of white petrolatum. The white petrolatum and cottonseed oil are heated to 145°C and then removed from the heat. The cholesterol is then added and stirred until it is almost congealed. Then the ointment is placed in suitable containers.

Example 9 Emulsion Base

The following formula illustrates an emulsion base that may be used according to the present invention. Many dermatologic and cosmetic preparations contain amine soaps as emulsifying agents. These anionic emulsifiers are advantageous as compared to sodium and potassium soaps because they yield emulsions having a relatively low pH of about 8.0. Triethanolamine is generally used, along with a fatty acid, to produce the fatty acid amine soap. Triethanolamine usually contains small amounts of ethanolamine and diethanolamine. It combines stoichiometrically with fatty acids. Semisolid O/W bases containing triethanolamine soaps are generally prepared by dissolving the triethanolamine in water and then adding this solution to the oil phase with stirring. A typical formula for such a base comprises 18 parts by weight stearic acid, 4 parts by weight of cetyl alcohol, 2 parts by weight of triethanolamine, 5 parts by weight of glycerin, and 71 parts by weight of distilled water.

Example 10 Coal Tar Ointment Base

The following formula illustrates an emulsion base that may be used according to the present invention. Coal tar ointment base contains a surfactant, i.e., polysorbate 80, which serves the dual purpose of a dispersing agent and aiding in removal of the ointment from the skin. Coal tar ointment comprises 10 parts by weight coal tar, 5 parts by weight polysorbate 80, and 985 parts by weight zinc oxide paste. The coal tar is blended with the polysorbate 80, and this blend is then mixed with the zinc oxide paste.

Example 1 1

Hvdrophilic Ointment Base The following formula illustrates an emulsion base that may be used according to the present invention. Hydrophilic ointment base comprises 0.25 parts by weight methylparaben, 0.15 parts by weight propylparaben, 10 parts by weight sodium lauryl sulfate, 120 parts by weight propylene glycol, 250 parts by weight stearyl alcohol, 250 parts by weight white petrolatum, and 370 parts by weight water. The stearyl alcohol and white petrolatum are melted on a steam bath and warmed to about 75°C. The other ingredients, previously dissolved in the water, are warmed to 75°C and then added with stirring until the mixture congeals. Example 12 Beeler's Base

The following formula illustrates an O/W emulsion base that may be used according to the present invention. Beeler's base comprises 15 parts by weight cetyl alcohol, Tparts by weight white wax, 10 parts by weight propylene glycol, 2 parts by weight sodium lauryl sulfate, and 72 parts by weight water. The cetyl alcohol and white wax are melted in the propylene glycol on a water bath, and the resulting mixture is heated to about 65°C. The sodium lauryl sulfate is dissolved in the water and also heated on water bath to about 65°C. The oil phase is slowly added to the well-stirred water phase, and stirring is continued on the water bath for about 10 min. The emulsion is then removed from the water bath and stirring is continued to the point of congealing.

Example 13 U.C.H. Base

The following formula illustrates an emulsion base that may be used according to the present invention. U.C.H. base comprises 6.4 parts by weight cetyl alcohol, 5.4 parts by weight stearyl alcohol, 1.5 parts by weight sodium lauryl sulfate, 14.3 parts by weight white petrolatum, 21.4 parts by weight mineral oil, and 50 parts by weight water. The alcohols are melted together over a water bath at 65⁰C, then the sodium lauryl sulfate is add with stirring. Next the white petrolatum and the mineral oil are added with continued heating of the mixture until it is completely melted. This mixture is then cooled to room temperature and the water is added with constant mixing to result in the emulsion. Example 14

Base A

The following formula illustrates an anhydrous emulsifϊable solid mixture. Anhydrous solid mixture A is made by melting together 53 parts by weight of stearyl alcohol, 7 parts by weight of cetyl alcohol, 38.6 parts by weight of PEG 400, and 1.4 parts by weight of sodium lauryl sulfate. These ingredients are melted and stirred vigorously until completely solidified. Stirring is continued to insure complete mixing of the ingredients and for the production of a granular product. Base A is made by melting 50 parts by weight of the granular solid mixture A, heating it to 70-75⁰C, and then adding it to 50 parts by weight of an aqueous mixture at the same temperature. The mixture is stirred until the emulsion begins to solidify and cools to 40⁰C. The resulting base is a white, semisolid O/W emulsion of ointment-like consistency. It is non-greasy and washable with water. The emulsion is stable up to 55-60⁰C, exhibits a good sheen, and exhibits good lubricity when applied to skin.

Example 15 Base B

The following formula illustrates an anhydrous emulsifiable solid mixture. Anhydrous solid mixture B is made by melting together 64.7 parts by weight of stearyl alcohol, 8.6 parts by weight of cetyl alcohol, 13 parts by weight of PEG 1000 monostearate, 8.7 parts by weight of PEG 1540, and 5 parts by weight of anhydrous lanolin. These ingredients are melted and stirred vigorously until completely solidified. Stirring is continued to insure complete mixing of the ingredients and for the production of a granular product. Base B is made by melting 40 parts by weight of the granular solid mixture B, heating it to 70-75⁰C, and then adding it to 60 parts by weight of an aqueous mixture at the same temperature. The mixture is stirred until the emulsion begins to solidify and cools to 40⁰C. The resulting base is a white, semisolid O/W emulsion of ointment-like consistency. It is non-greasy and washable with water. The emulsion is stable up to 55-60⁰C and exhibits good lubricity when applied to skin.

Example 16 Aqueous Cream Base The following formula illustrates an emulsion base that may be used according to the present invention. Aqueous cream base is an emulsion base prepared from 30% by weight of emulsifying ointment and 70% by weight of water. Emulsifying ointment comprises 30 parts by weight emulsifying wax, 20 parts by weight liquid paraffin, and 50 parts by weight white soft paraffin. Emulsifying wax comprises 90 parts by weight cetostearyl alcohol, 10 parts by weight sodium lauryl sulfate, and 4 parts by weight purified water. Example 17

Polyethylene Glycol Ointment Base

The following formula illustrates a water-soluble base that may be used according to the present invention. Polyethylene glycol ointment base comprises 400 parts by weight of PEG 4000 and 600 parts by weight of PEG 400. The two ingredients are heated on a water bath to 65°C, and then the mixture is allowed to cool with stirring until it congeals. If a firmer preparation is desired, up to 100 parts by weight of the PEG 400 may be replaced with an equal amount of PEG 4000. If 6-25% by weight of an aqueous solution is to incorporated in this polyethylene ointment, 50 parts by weight of the PEG 4000 is replaced with an equal amount of stearyl alcohol.

Example 18 Base G

The following formula illustrates a water-soluble base that may be used according to the present invention. The addition of an ester of polyethylene glycol to a polyethylene glycol ointment yields a water- removable, emulsifiable ointment base. An illustrative emulsifiable glycol ointment base (Base G) of this type comprises 26 parts by weight polyethylene glycol 400 monostearate, 37 parts by weight PEG 400, and 37 parts by weight PEG 4000. The glycols are mixed and melted at about 65°C. This mixture is then stirred while cooling to about 40⁰C. The polyethylene glycol 400 monostearate is melted at about 40°C and then added to the liquid glycol mixture with stirring until a uniform ointment is obtained. Water (10-15% by weight) may be incorporated into Base G.

Example 19 Base III

The following formula illustrates a water-soluble base that may be used according to the present invention. Surfactants and water may be added to a polyethylene glycol ointment without impairing the water removability of the base. Base III represents a typical formula of this type: 50 parts by weight PEG 4000, 40 parts by weight PEG 400, 1 parts by weight sorbitan monopalmitate, and 9 parts by weight water. The sorbitan monopalmitate and the polyethylene glycols are warmed together on a water bath to 70⁰C and the water heated to the same temperature is then added. The emulsion is stirred until it congeals.

Example 20 Modified Landon-Zopf Base

The following formula illustrates a water-soluble base that may be used according to the present invention. Modified Landon-Zopf base comprises 20 parts by weight PEG 4000, 34 parts by weight stearyl alcohol, 30 parts by weight glycerin, 15 parts by weight water, and 1 parts by weight sodium iauryl sulfate. The PEG 4000, stearyl alcohol, and glycerin are heated on a water bath to 75°C. This mixture is then added in small quantities with stirring to the water, which contains the sodium lauryl sulfate and has also been heated to 75⁰C. Moderate stirring is continued until the base has congealed.

Example 21 Canadian Base

The following formula illustrates a water-soluble base that may be used according to the present invention. Canadian base comprises 11.2 parts by weight PEG 4000, 20.8 parts by weight stearyl alcohol, 17 parts by weight glycerin, 0.6 parts by weight sodium lauryl sulfate, and 50.4 parts by weight water. The PEG 4000, stearyl alcohol, and glycerin are heated on a water bath to 70⁰C. The water, which contains the sodium lauryl sulfate and has been previously heated to 70°C, is added and the mixture is stirred until the base congeals.

Example 22 Base IV

The following formula illustrates a water-soluble base that may be used according to the present invention. Base IV comprises 42.5 parts by weight PEG 4000, 37.5 parts by weight PEG 400, and 20 parts by weight 1,2,6-hexanetriol. The PEG 4000 is heated with the 1,2,6-hexanetriol is heated on a water bath to 60-70⁰C. This mixture is added to the PEG 400 at room temperature with vigorous stirring. The, occasional stirring is continued until solidification takes place.

Example 23 Glyceryl Monostearate Base

The following formula illustrates a water-soluble base that may be used according to the present invention. Glyceryl monostearate base comprises 10 parts by weight mineral oil, 30 parts by weight white petrolatum, 10 parts by weight glyceryl monostearate S. E., 5 parts by weight cetyl alcohol, 5 parts by weight glycerin, and 40 parts by weight water. Example 24

Lubricating Jelly Base

The following formula illustrates a water-soluble base that may be used according to the present invention. Lubricating jelly base comprises 1 g methocel 90 HC 4000, 0.3 g carbopol 934, sodium hydroxide qs pH 7.0, 20 ml propylene glycol, 0.15 g methylparaben, and purified water qs 100 parts by weight. The methocel is added slowly to 40 ml of hot water (80-90⁰C) and agitated for 5 min. After cooling, the solution is refrigerated overnight. The carbopol 934 is dissolved in 20 ml of water, and 1% sodium hydroxide is added slowly with cautious stirring to avoid incorporation of air, until a pH of 7.0 is obtained, and then water is added to a total volume of 40 ml. The methylparaben is dissolved in the propylene glycol. Finally the methocel, Carbopol^®, and methylparaben solutions are mixed cautiously to avoid incorporation of air.

Example 25 Universal O/W Ointment Base

The following formula illustrates a water-soluble base that may be used according to the present invention. Universal O/W ointment base comprises 0.05 parts by weight calcium citrate, 3 parts by weight sodium alginate, 0.20 parts by weight methylparaben, 45 parts by weight glycerin, and sufficient distilled water to make a total of 100 parts by weight. The calcium citrate and the methylparaben are dissolved in the water. The glycerin is mixed with the sodium alginate to form a smooth paste. The aqueous mixture is added to the paste and is stirred until a smooth, stiff preparation is obtained. The base is then set aside for several hours until thickening is complete.

Example 26 Hollander and McClanahan Base

The following formula illustrates a water-sohible base that may be used according to the present invention. Hollander and McClanahan base comprises 32 parts by weight petrolatum, 13 parts by weight bentonite, 0.5 parts by weight sodium lauryl sulfate, 54 parts by weight water, and 0.1 parts by weight methylparaben. Example 27

MGH Ointment Base

The following formula illustrates a water-soluble base that may be used according to the present invention. MGH ointment base comprises 15 parts by weight polyethylene glycol 200 monostearate, 2.5 parts by weight colloidal magnesium stearate silicate (Veegum^®), 1 parts by weight polysorbate 80, 0.1 parts by weight methylparaben, and 81.4 parts by weight purified water.

Example 28 Lotion Base

The following formula illustrates a water-soluble base that may be used according to the present invention. Lotion base comprises 1 parts by weight Veegum^®, 0.85 parts by weight sodium carboxymethylcellulose, 90.15 parts by weight water, 3 parts by weight glycerin, and 5 parts by weight dioctyl sodium sulfosuccinate (1% solution). All the dry ingredients are mixed with water and glycerin in a blender for 1 min. The mixture is then removed from the blender and the dioctyl sodium sulfosuccinate is added.

Example 29 Cold Cream Base

The following formula illustrates a cold cream according to an illustrative embodiment of the present invention. A cold cream base comprises 6 parts by weight spermaceti, 6 parts by weight beeswax, 10 parts by weight Carbopol 934, 4.75 parts by weight sodium carbonate, 5 parts by weight rose water, 0.02 parts by weight rose oil, 56 parts by weight expressed almond oil, and 20 parts by weight distilled water. Example 30

Hand Lotion Base

The following formula illustrates a hand lotion according to an illustrative embodiment the present invention. A hand lotion base comprises 24.75 ml propylene glycol, 1 ml triethanolamine, 12 ml water, 1.5 g oleic acid, 10.5 g polyethylene glycol 400 monostearate, 10 ml silicone fluid D.C. 200, and 50 g carbopol 934 2% mucilage.

Example 31 White Lotion Base

The following formula illustrates a hand lotion according to an illustrative embodiment of the present invention. White lotion base comprises 40 parts by weight zinc sulfate, 40 parts by weight sulfiirated potash, and sufficient purified water to make 1000 parts by weight. The zinc sulfate and the sulfurated potash are dissolved separately, each in 450 parts by weight of purified water, and then each solution is

Claims

CLAIMS The subject matter claimed is:

1. A skin care composition comprising a mixture of partially hydrolyzed fucoidan and a base.

2. The skin care composition of claim 1 comprising about 1 to about 95 weight percent of the partially hydrolyzed fucoidan.

3. The skin care composition of claim 1 , wherein the partially hydrolyzed fucoidan comprises a derivative of one of the group of: Japanese mozuku seaweed, Japanese kombu seaweed, Tongan limu moui seaweed, and combinations thereof.

4. The skin care composition of claim 1 , wherein the partially hydrolyzed fucoidan comprises a derivative of Tongan limu moui seaweed.

5. The skin care composition of claim 1, wherein the partially hydrolyzed fucoidan is sulfonated.

6. ^' The skin care composition of claim 1 wherein the base comprises an oleaginous base.

7. The skin care composition of claim 6 wherein the oleaginous base comprises a hydrocarbon base.

8. The skin care composition of claim 6 wherein the oleaginous base comprises a silicone polymer.

9. The skin care composition of claim 6 wherein the oleaginous base comprises a vegetable oil.

10. The skin care composition of claim 6 wherein the oleaginous base comprises an animal fat.

11. The skin care composition of claim 1 wherein the base comprises an absorption base.

12. The skin care composition of claim 1 wherein the base comprises an emulsion base.

13. The skin care composition of claim 12 wherein the emulsion base comprises an aqueous phase, an emulsifying agent, and an oleaginous phase.

14. The skin care composition of claim 1 wherein the base comprises a water-soluble base.

15. The skin care composition of claim 14 wherein the water-soluble base comprises a member selected from the group consisting of polyethylene glycols, bentonite, colloidal magnesium aluminum silicate, sodium alginate, glyceryl monostearate, cellulose derivatives, and mixtures thereof.

16. The skin care composition of claim 14 wherein the water-soluble base is a cellulose derivative selected from the group consisting of methylcellulose, hydroxyethyl cellulose, and sodium carboxymethyl cellulose, and mixtures thereof.

17. A skin moisturizing composition comprising a mixture of: a partially hydrolyzed, sulfonated fucoidan, wherein the fucoidan is a derivative of Tongan limu moui seaweed; and a base.

18. A method of making a skin moisturizing composition comprising combining partially hydrolyzed fucoidan and a base.

19. The method of making a skin moisturizing composition of claim 18, further comprising preparing the partially hydrolyzed fucoidan by: harvesting Tongan limu moui seaweed; removing extraneous material; mixing the Tongan limu moui seaweed with an aqueous buffer while heating; and filtering.

20. The method of making a skin moisturizing composition of claim 19, wherein the step of mixing the Tongan limu seaweed with an aqueous buffer further comprises the step of adding sulfuric acid.

21. A skin care composition for the care of wrinkles, comprising partially hydrolyzed fucoidan, a base, and an anti-wrinkle compound.

22. The skin care composition of claim 21, wherein the partially hydrolyzed fucoidan is sulfonated.

23. The skin care composition of claim 21, wherein the partially hydrolyzed fucoidan comprises derived from the group consisting of: Japanese mozuku seaweed, Japanese kombu seaweed, Tongan limu moui seaweed, and combinations thereof. ■

24. The skin care composition of claim 21, comprising from about -1 to about 95 weight percent of the partially hydrolyzed fucoidan.

25. The skin care composition of claim 21 , further comprising a derivative of mangosteen plant.

26. The skin care composition of claim 21 , further comprising honey.

27. The skin care composition of claim 21, wherein the anti-wrinkle compound comprises a flavonoid.

28. The skin care composition of claim 27, wherein the flavonoid comprises one of the group consisting of: unsubstituted flavanone, mono-hydroxy flavanones, mono alkoxy flavanones, unsubstituted chalcone, mono-hydroxy chalcones, di-hydroxy chalcones, and tri-hydroxy chalcones, unsubstituted flavone, 7,2'-dihydroxy flavone, 3',4'-dihydroxy naphthoflavone, 4'- hydroxy flavone, 5,6-benzoflavone, and 7,8- benzoflavone, unsubstituted isoflavone, daidzein, 5,7-dihydroxy-4'- methoxy isoflavone, soy isoflavones, unsubstituted coumarin, 4-hydroxy coiunarin, 7-hydroxy coumarin, 6-hydroxy- 4-methyl coumarin, unsubstituted chromone, 3-formyl chromone, 3-formyl-6- isopropyl chromone, unsubstituted dicoumarol, unsubstituted chromanone, unsubstituted chromanol, and mixtures thereof.

29. The skin care composition of claim 21 wherein the base comprises an oleaginous base.

30. The skin care composition of claim 29 wherein the oleaginous base comprises a hydrocarbon base.

31. The skin care composition of claim 29 wherein the oleaginous base comprises a silicone polymer.

32. The skin care composition of claim 29 wherein the oleaginous base comprises a vegetable oil.

33. The skin care composition of claim 21 , further including a radiation protection agent.

34. The skin care composition of claim 21 wherein the base comprises an absorption base.

35. The skin care composition of claim 21 wherein the base comprises an emulsion base.

36. The skin care composition of claim 35 wherein the emulsion base comprises an aqueous phase, an emulsifying agent, and an oleaginous phase.

37. The skin care composition of claim 21 wherein the base comprises a water-soluble base.

38. The skin care composition of claim 37 wherein the water-soluble base comprises a member selected from the group consisting of polyethylene glycols, bentonite, colloidal magnesium aluminum silicate, sodium alginate, glyceryl monostearate, cellulose derivatives, and mixtures thereof.

39. The skin care composition of claim 37 wherein the water-soluble base is a cellulose derivative selected from the group consisting of methylcellulose, hydroxyethyl cellulose, and sodium carboxymethyl cellulose, and mixtures thereof.

40. A method of making a skin care composition for the care of wrinkles, comprising the steps of: producing partially hydrolyzed fucoidan by: harvesting Tongan limu moui seaweed; removing extraneous material; mixing the Tongan limu moui seaweed with an aqueous buffer while heating; and, filtering; and mixing the partially hydrolyzed fucoidan with a base and an anti-wrinkle compound.

41. A composition for skin protection from ultraviolet damage to be applied to skin or hair, comprising a mixture of partially hydrolyzed fucoidan, a base, and a radiation protecting agent.

42. The composition of claim 41, wherein the partially hydrolyzed fucoidan comprises from about 0.05 to about 95 weight percent of the composition.

43. The composition of claim 41, wherein the partially hydrolyzed fucoidan includes a derivative of one seaweed of the group consisting of: Tongan limu moui seaweed, Japanese mozuko seaweed, Japanese kombu seaweed, and combinations thereof.

44. The composition of claim 41, wherein the partially hydrolyzed fucoidan is sulfonated.

45. The composition of claim 41, wherein the radiation, protecting agent includes titanium dioxide.

46. The composition of claim 41, wherein the radiation protecting agent includes one selected from the group consisting of: />-aminobenzoic acid (PABA), avobenzone, cinoxate, dioxybenzone, homosalate, menthyl anthranilate, octocrylene, octyl methoxycinnamate (Octinoxate), octyl salicylate, oxybenzone, padimate O, phenylbenzimidazole sulfonic acid, sulisobenzone, trolamine salicylate, aminobenzoic acid, 2-ethylhexyI-/> methoxycinnamate, 4,4'-/-butylmethoxydibenzoyl-methane, 2-hydroxy 4- methoxybenzophenone, octyldimethyl-p-aminobenzoic acid, digalloyltrioleate, 2,2-dihydroxy-4- methoxybenzophenone, ethyl-4-(bis(hydroxy-propyl))aminobenzoate, 2-ethylhexyl-2-cyano-3,3- diphenylacrylate., 2-ethylhexyl-salicylate, glyceryl-/j-aminobenzoate, S^jS-tri-methylcyclohexylsalicylate, methylanthraniIate,/7-dimethyl-aminobεnzoic acid or aminobenzoate, 2-ethylhexyl-p-dimethyl- aminobεnzoate, 2-phenylbenzimidazole-5-sulfonic acid, 2-(p-dimethylaminophenyl)-5-suIfonicbenzoxazoic acid, ensulizole, meradimate, octocrylene, titanium dioxide, zinc oxide, and mixtures thereof.

47. The composition of claim 41, wherein the base comprises an oleaginous base.

48. The composition of claim 47, wherein the oleaginous base comprises a hydrocarbon base.

49. The composition of claim 41, wherein the base is an absorption base.

50. The composition of claim 49, wherein the base is an aqueous base, an emulsifying agent, and an oleaginous phase.

51. The composition of claim 41, wherein the base comprises a water-soluble base.

52. The composition of claim 41, further comprising an analgesic.

53. The composition of claim 41, further comprising mangosteen.

54. The composition of claim 53, wherein the composition comprises from about 0.01 to about 10 weight percent mangosteen.

55. The composition of claim 41, further comprising an antioxidant.

56. The composition of claim 55, wherein the antioxidant comprises one of the group consisting of: butylated hydroxy benzoic acid, ό-hydroxy^S^.S-tetrameΛylchrornan^-carboxylic acid, gallic acid, propyl gallate, uric acid, sorbic acid, ascorbyl esters of fatty acids, amines, dihydroxy fumaric acid, and mixtures thereof.

57. The composition of claim 41, wherein the base is substantially clear.

58. A composition for skin protection from ultraviolet damage for application to skin or hair, comprising a mixture of: sulfonated and partially hydrolyzed fucoidan derived from Tongan limu moui seaweed; a base; and a radiation protecting agent.

59. The composition of claim 58, wherein the radiation protecting agent is titanium dioxide.

60. The composition of claim 58, wherein the base is substantially clear.

61. An article with skin-protecting and moisturizing compound, comprising: a tissue substrate, a base and partially hydrolyzed fucoidan.

62. The article of claim 61, wherein the partially hydrolyzed fucoidan is a derivative of one of the group consisting of: Tongan limu moui seaweed, Japanese wakame seaweed, Japanese mozuku seaweed, and combinations thereof.

63. The article of claim 61, wherein the fucoidan is sulfonated.

64. The article of claim 61 , wherein the partially hydrolyzed fucoidan comprises from about 0.05 weight percent to about SO weight percent of the tissue.

65. The article of claim 61 , further comprising an anti-viral agent.

66. The article of claim 65, wherein the anti-viral agent comprises pyrrolidone carboxylic acid.

67. The article of claim 65, wherein the anti-viral agent comprises a metal salt.

68. The article of claim 61, further comprising one of the additives selected from the group consisting of: honey, mangosteen, witch hazel, sage, piper, clove, ginger, red pepper, willow, rhubarb, sesame, chamomile, propolis, thyme, lavender, cinnamon oil, flower or blossom oils, olive oil, palm oil, coconut oil, beeswax, and combinations thereof.

69. A method of making an article with skin-protecting and moisturizing compound, comprising: providing a first tissue paper web; applying a base to the first tissue paper web; and applying partially hydrolyzed fucoidan to the tissue paper web.

70. The method of claim 69, further comprising the step of applying a second tissue paper web to the first tissue paper web.

71. The method of claim 69, further comprising applying an anti-viral agent to the first tissue paper web.

72. The method of claim 70, further comprising applying an anti-viral agent to the second tissue paper web.

73. The method of claim 69, wherein the base and the partially hydrolyzed fucoidan are combined before application to the tissue paper web.

74. The method of claim 69, wherein the partially hydrolyzed fucoidan is sulfonated.

75. The method of claim 69, wherein the partially hydrolyzed fucoidan is a derivative of one of the group consisting of: Tongan limu moui seaweed, Japanese wakarne seaweed, Japanese mozuku seaweed, and combinations thereof.